Elite Pharmaceuticals, Inc. revenue by segment ELTP

Annual Quarterly

Elite Pharmaceuticals, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2026, which ended Mar 31, 2026 was Indirect Sales To Wholesalers at $82.5 million, 55% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2027 Jun 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019	FY 2018 Mar 31, 2018	FY 2017 Mar 31, 2017
Revenue	141	149	84	57	34	32	25	18	8	7	10
Indirect Sales To Wholesalers	—	83 +142.9% share 55.4%	34 share 40.4%	—	—	—	—	—	—	—	—
Direct Sales To Wholesalers	—	65 +36.0% share 43.8%	48 share 57.1%	—	—	—	—	—	—	—	—
Abbreviated New Drug Applications Revenue	—	—	—	54 +85.4% share 95.6%	29 share 85.5%	—	—	—	—	—	—
Un Scheduled Products Manufacturing Fees	—	6 -12.2% share 4.3%	7 share 8.6%	—	—	—	—	—	—	—	—
Licensing	—	1 -48.5% share 0.7%	2 -17.8% share 2.4%	3 -49.6% share 4.4%	5 share 14.5%	—	—	—	—	—	—
Scheduled Products Licensing Fees	—	0 +87.1% share 0.3%	0 share 0.3%	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ELTP (OTC)
Fiscal year ends: March 31
Incorporated in: NJ
Headquarters: Northvale, NJ
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1053369
Former names: ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.